Literature DB >> 31410511

[Stereotactic ablative radiotherapy confirmed as a standard technique in NSCLC stage I].

Markus Hecht1, Rainer Fietkau2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31410511     DOI： 10.1007/s00066-019-01503-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.

Authors:  Jan Nyman; Andreas Hallqvist; Jo-Åsmund Lund; Odd-Terje Brustugun; Bengt Bergman; Per Bergström; Signe Friesland; Rolf Lewensohn; Erik Holmberg; Ingmar Lax
Journal:  Radiother Oncol       Date:  2016-09-03       Impact factor: 6.280

3.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.

Authors:  Robert Timmerman; Ronald McGarry; Constantin Yiannoutsos; Lech Papiez; Kathy Tudor; Jill DeLuca; Marvene Ewing; Ramzi Abdulrahman; Colleen DesRosiers; Mark Williams; James Fletcher
Journal:  J Clin Oncol       Date:  2006-10-20       Impact factor: 44.544

4.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.